Delivering advanced therapies: the big pharma approach.

After two decades of focused development and some recent clinical successes, cell and gene therapy (CGT) is emerging as a promising approach to personalized medicines. Genetically engineered cells as a medical modality are poised to stand alongside or in combination with small molecule and biopharmaceutical approaches to bring new therapies to patients globally. Big pharma can have a vital role in industrializing CGT by focusing on diseases with high unmet medical need and compelling genetic evidence. Pharma should invest in manufacturing and supply chain solutions that deliver reproducible, high-quality therapies at a commercially viable cost. Owing to the fast pace of innovation in this field proactive engagement with regulators is critical. It is also vital to understand the needs of patients all along the patient care pathway and to establish product pricing that is accepted by prescribers, payers and patients.

Synthesis of the large subunit of ribulose-1,5-bisphosphate carboxylase in anin vitro partially definedE. coli system.

Thein vitro DNA- or RNA-directed synthesis of the large subunit (LS) of spinach chloroplast ribulose-1,5-biphosphate carboxylase (RuP2C) has been examined in a highly definedE. coli transcription-translation system. Spinach chloroplast DNA, RNA and recombinant plasmids containing the spinach chloroplast LS gene (rbcL) have been used as templates in thein vitro system and a quantitative assay has been developed to measure LS formation. Thein vitro formed product contains formylmethionine at the N-terminal position and sediments primarily as a monomer. There is no detectable enzymatic activity associated with thein vitro product. To determine where theE. coli RNA polymerase used in these systems initiates, we have examined the transcripts produced by this enzymein vitro. Measurements of run-off transcripts indicate thatE. coli RNA polymerase initiates at the same position on the gene as is seenin vivo. In addition, the complete nucleotide sequence of therbcL gene including previously unsequenced 3' and 5' flanking regions has been determined. The sequence agrees, except at two nucleotide positions, with previously published sequencing data for this gene (Zurawski, G, Perrot, B, Bottomley, W, Whitfeld, PR, 1981. Nucleic Acids Res. 9:3251-3270).

Cloning, mapping, and in vitro transcription-translation of the gene for the large subunit of ribulose-1,5-bisphosphate carboxylase from spinach chloroplasts.

An 11.2-kilobase pair (kbp) BamHI restriction nuclease fragment from spinach chloroplast DNA has been found to contain the gene for the large subunit (LS) of ribulose-1,5-bisphosphate carboxylase [RuP(2) carboxylase; 3-phospho-D-glycerate carboxy-lyase (dimerizing), EC 4.1.1.39]. The gene was located by hybridization of cloned chloroplast DNA fragments containing the maize LS gene (Bedbrook, J. R., Coen, D. M., Beaton, A. R., Bogorad, L. & Rich, A. (1979) J. Biol. Chem. 254, 905-910) to spinach chloroplast DNA cleaved with restriction nucleases. The 11.2-kbp BamHI fragment has been inserted into the BamHI site of the plasmid pBR322. The resulting recombinant plasmid, pSoe3101, was used to direct the synthesis of a protein, which was immunoprecipitable with antibody to RuP(2) carboxylase, in a partially defined in vitro transcription-translation system derived from Escherichia coli. The product synthesized in vitro has a molecular weight identical to that of authentic spinach LS. By using pSoe3101 DNA cleaved at various positions with restriction nucleases, and the in vitro transcription-translation system, the LS gene has been mapped to a 1.5-kbp region located at one end of the 11.2-kbp BamHI fragment. The direction of transcription of the LS gene on the plasmid as well as on the chloroplast chromosome has also been determined. The position of the LS gene on circular spinach chloroplast DNA is approximately 27 kbp from the start of one of the inverted repeat regions and 180 degrees from one of the rRNA-coding regions.

Euglena gracilis chloroplast EF-Ts. Evidence that it is a nuclear-coded gene product.

Extracts of Euglena gracilis cells contain high levels of elongation factor (EF)-Ts (EF-Tschl) activity which can be assayed by measuring the rate of exchange of GDP with Escherichia coli EF-Tu . GDP. The appearance of EF-Ts activity in E. gracilis cells is light-stimulated, suggesting that the EF-Ts is required for chloroplast function. However, based on experiments with a mutant of E. gracilis lacking chloroplast DNA, as well as studies on the effect of antibiotics on EF-Ts synthesis, it is concluded that the EF-Tschl gene is nuclear-coded.